[go: up one dir, main page]

WO2008132167A3 - Indicateurs de diagnostic, de pronostic et/ou prédictifs du cancer du sein - Google Patents

Indicateurs de diagnostic, de pronostic et/ou prédictifs du cancer du sein Download PDF

Info

Publication number
WO2008132167A3
WO2008132167A3 PCT/EP2008/055077 EP2008055077W WO2008132167A3 WO 2008132167 A3 WO2008132167 A3 WO 2008132167A3 EP 2008055077 W EP2008055077 W EP 2008055077W WO 2008132167 A3 WO2008132167 A3 WO 2008132167A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognostic
diagnostic
breast cancer
predictive indicators
potential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/055077
Other languages
English (en)
Other versions
WO2008132167A2 (fr
Inventor
Lorraine O'driscoll
Padraig Doolan
Martin Clynes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dublin City University
Original Assignee
Dublin City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dublin City University filed Critical Dublin City University
Publication of WO2008132167A2 publication Critical patent/WO2008132167A2/fr
Publication of WO2008132167A3 publication Critical patent/WO2008132167A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un nouveau panneau de marqueurs d'ARNm qui ont un potentiel en tant qu'indicateurs de diagnostic, de pronostic et/ou prédictifs du cancer du sein. Des éléments de ce panneau ont également un potentiel en tant que nouvelles cibles thérapeutiques.
PCT/EP2008/055077 2007-04-26 2008-04-25 Indicateurs de diagnostic, de pronostic et/ou prédictifs du cancer du sein Ceased WO2008132167A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE2007/0308 2007-04-26
IE20070308 2007-04-26

Publications (2)

Publication Number Publication Date
WO2008132167A2 WO2008132167A2 (fr) 2008-11-06
WO2008132167A3 true WO2008132167A3 (fr) 2009-03-12

Family

ID=39730839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055077 Ceased WO2008132167A2 (fr) 2007-04-26 2008-04-25 Indicateurs de diagnostic, de pronostic et/ou prédictifs du cancer du sein

Country Status (1)

Country Link
WO (1) WO2008132167A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080865A1 (it) * 2008-05-13 2009-11-14 Istituto Naz Di Genetica Molecolare Ingm Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3
WO2013025952A2 (fr) * 2011-08-16 2013-02-21 Oncocyte Corporation Procédés et compositions pour le traitement et le diagnostic du cancer du sein
US20140328840A1 (en) * 2011-10-21 2014-11-06 The Provost, Fellows, Foundation Scholars, and the Other Members of the Board, of the College of the Marker and target for responsiveness and resistance to cancer agents
GB2496150A (en) * 2011-11-02 2013-05-08 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Biomarker and target for responsiveness and resistance to cancer targeting agents
SG11201707067UA (en) * 2015-03-12 2017-09-28 Agency Science Tech & Res A multigene assay
AT521641B1 (de) * 2018-09-12 2020-07-15 Fianostics Gmbh Verfahren zur Diagnose von Lebererkrankungen
CN115838802B (zh) * 2022-08-29 2025-03-07 山东第一医科大学第一附属医院(山东省千佛山医院) lncRNA PTPRN2-AS1作为肾透明细胞癌预后标志物的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002073207A2 (fr) * 2001-03-08 2002-09-19 Cytyc Health Corporation Echantillon de fluide canalaire isole
WO2006022895A2 (fr) * 2004-08-02 2006-03-02 Children's Medical Center Corporation Biomarqueurs de plaquettes servant a detecter le cancer
WO2006086638A2 (fr) * 2005-02-10 2006-08-17 Board Of Regents, The University Of Texas System Ciblage d'un facteur pro-apoptotique secrete a des fins de carcinotherapie
WO2007098102A2 (fr) * 2006-02-17 2007-08-30 Children's Medical Center Corporation Ngal libre en tant que biomarqueur de cancer
WO2008079269A2 (fr) * 2006-12-19 2008-07-03 Genego, Inc. Nouveaux procédés pour une analyse fonctionnelle de données expérimentales à haut débit et groupes de gènes identifiés à partir de ceux-ci

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002073207A2 (fr) * 2001-03-08 2002-09-19 Cytyc Health Corporation Echantillon de fluide canalaire isole
WO2006022895A2 (fr) * 2004-08-02 2006-03-02 Children's Medical Center Corporation Biomarqueurs de plaquettes servant a detecter le cancer
WO2006086638A2 (fr) * 2005-02-10 2006-08-17 Board Of Regents, The University Of Texas System Ciblage d'un facteur pro-apoptotique secrete a des fins de carcinotherapie
WO2007098102A2 (fr) * 2006-02-17 2007-08-30 Children's Medical Center Corporation Ngal libre en tant que biomarqueur de cancer
WO2008079269A2 (fr) * 2006-12-19 2008-07-03 Genego, Inc. Nouveaux procédés pour une analyse fonctionnelle de données expérimentales à haut débit et groupes de gènes identifiés à partir de ceux-ci

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLEATOR S, ASHWORTH A: "Molecular profiling f breast cancer: clinical implications", BRITISH JOURNAL OF CANCER, vol. 90, 2004, pages 1120 - 1124, XP002496411 *
FERNÁNDEZ CECILIA A ET AL: "The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5390 - 5395, XP002440683, ISSN: 1078-0432 *
STOESZ S P ET AL: "HETEROGENELOUS EXPRESSION OF THE LIPOCALIN NGAL IN PRIMARY BREAST CANCERS", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 79, 1 January 1998 (1998-01-01), pages 565 - 572, XP000979576, ISSN: 0020-7136 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2008132167A2 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2012068383A3 (fr) Arnnc et utilisations de celui-ci
WO2007123772A3 (fr) Gènes impliqués dans le métabolisme des oestrogènes
EP3124624A3 (fr) Marqueurs de methylation du cancer des poumons
WO2008046911A3 (fr) Nouveaux microarn humains associés au cancer
WO2010081001A3 (fr) Fusions de gène récurrent dans le cancer
WO2011087845A3 (fr) Profilage métabolomique du cancer de la prostate
WO2010017515A3 (fr) Marqueurs spécifiques du cancer du sein et procédés d’utilisation
WO2008132167A3 (fr) Indicateurs de diagnostic, de pronostic et/ou prédictifs du cancer du sein
WO2011034906A3 (fr) Fusions de gène récurrentes dans le cancer de la prostate
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2012174256A3 (fr) Profils de méthylation de l'adn dans le cancer
WO2009038689A3 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
WO2009108860A8 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
WO2008089397A3 (fr) Marqueurs du cancer adrb2
EP3054299A3 (fr) Biomarqueurs pour la détection précoce du cancer du sein
WO2008104543A3 (fr) Procédé de prévision de l'occurrence de métastases chez des patients souffrant de cancer du sein
WO2011002834A3 (fr) Compositions et procédés de diagnostic et de traitement du diabète de type i
WO2008104380A3 (fr) Détection multiple de cellules tumorales utilisant plusieurs agents se fixant à des marqueurs extracellulaires
WO2010099161A8 (fr) Microarn chez les non-fumeurs et méthodes et matières apparentées
WO2009092108A3 (fr) Biomarqueurs pour le diagnostic et le traitement du cancer du pancréas
WO2008046509A8 (fr) Protéine ltbp2 utilisée en tant que biomarqueur, cible thérapeutique et diagnostique
WO2008097908A3 (fr) Procédés de diagnostic et de pronostic d'un cancer du poumon
WO2011088149A3 (fr) Procédés pour prédire la réponse d'un cancer du sein triple négatif à une thérapie
WO2009036427A3 (fr) Biomarqueurs du cancer de la prostate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08749737

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08749737

Country of ref document: EP

Kind code of ref document: A2